Skip to main content
Equibles
TXG logo

TXG · 10x Genomics, Inc. · Metrics

Track TXG — free

Use TXG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TXG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$88.76 -1.60 (-1.77%) At close · Oct 1
Russell 2000 member Rebalance outlook locked
Market Cap
$11.17B
Shares
130.29M
Volume · Oct 1 3.25M Avg daily vol (3M) 3.03M

TXG metrics

74 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$88.76
Market cap
$11.17B

Price action

20 metrics
Price change (1W)
+19.5%
Price change (30D)
+50.7%
Price change (3M)
+131.4%
Price change (6M)
+309.8%
Price change (YTD)
+454.0%
Price change (1Y)
+673.0%
Trailing year
Price change (5Y)
-37.9%
52-week high
$90.36
52-week low
$11.47
Change from 52-week high
+0.0%
Change from 52-week low
+687.8%
Annualized volatility
72.8%
Annualized volatility (3M)
74.2%
Beta
2.2
RSI (14D)
77.2
Price vs SMA 50
+43.3%
Price vs SMA 200
+165.8%
Avg volume (3M)
3.03M
Relative volume
1.2
Average dollar volume
$179.37M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
130.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
18.1×
reciprocal yield 5.5%
P / book
13.5
reciprocal yield 7.4%
FCF yield
1.1%
TTM · current market cap
Buyback yield
—
P / FCF
92.0
reciprocal yield 1.1%
P / operating cash flow
87.9
reciprocal yield 1.1%
Earnings yield
-0.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
49.2×
reciprocal yield 2.0%
EV / revenue historical average (5Y)
49.2×
reciprocal yield 2.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
70.0%
Operating margin
-14.3%
Trailing 12 months
Net margin
-12.2%
Gross profit (TTM)
$432.03M
Operating profit (TTM)
−$88.38M
Net income (TTM)
−$75.12M
Trailing 12 months
Diluted EPS (TTM)
$-0.59
FCF margin
19.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$6.24

Growth

11 metrics
Revenue growth YoY
-12.6%
Year over year
Net income growth YoY
-151.9%
Revenue (TTM)
$616.91M
Trailing 12 months
EPS growth YoY
-150.0%
Shares change YoY
+4.4%
Year over year · more shares
Revenue CAGR (3Y)
+7.6%
Revenue CAGR (5Y)
+16.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-9.1%
Return on assets
-7.3%
Debt / equity
—
Current ratio
5.7
EBITDA (TTM)
−$48.40M
Free cash flow (TTM)
$121.44M
Quick ratio
5.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$502.51M
Total assets
$1.03B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$127.08M
Capital expenditures (TTM)
$5.65M
R&D (TTM)
$226.80M
SG&A (TTM)
$297.01M
Stock compensation (TTM)
$98.74M
R&D / revenue
36.8%
Stock compensation / revenue
16.0%

Ownership (13F)

3 metrics
13F filers
394
13F filer change QoQ
+59
Institutional ownership
99.2%

Short interest

3 metrics
Short interest
12.8%
Latest settlement · 7.1 days to cover
Days to cover
7.1d
Short-squeeze score
83 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$12.24M
Insider-sentiment score
15 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1770787 CUSIP 88025U109 13F (30d) 12 filings 10 filers Visit website Investor relations